172 related articles for article (PubMed ID: 10864338)
41. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
42. Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
Perabò M; Fink V; Günthner-Biller M; von Bodungen V; Friese K; Dian D
Arch Gynecol Obstet; 2014 Jun; 289(6):1325-30. PubMed ID: 24389920
[TBL] [Abstract][Full Text] [Related]
43. Prophylactic surgery in hereditary breast/ovarian cancer syndrome.
Levine DA; Gemignani ML
Oncology (Williston Park); 2003 Jul; 17(7):932-41; discussion 946-8, 950-2. PubMed ID: 12886864
[TBL] [Abstract][Full Text] [Related]
44. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
45. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
[TBL] [Abstract][Full Text] [Related]
47. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
48. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL
Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974
[TBL] [Abstract][Full Text] [Related]
49. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2-positive patient.
Spear SL; Pennanen M; Barter J; Burke JB
Plast Reconstr Surg; 1999 Feb; 103(2):548-53; discussion 554-5. PubMed ID: 9950543
[No Abstract] [Full Text] [Related]
51. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
52. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.
Wang G; Beattie MS; Ponce NA; Phillips KA
Genet Med; 2011 Dec; 13(12):1045-50. PubMed ID: 21844812
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR; Levin AM; Eisen A; Snyder C; Watson P; Cannon-Albright L; Isaacs C; Olopade O; Garber JE; Godwin AK; Daly MB; Narod SA; Neuhausen SL; Lynch HT; Weber BL
J Natl Cancer Inst; 1999 Sep; 91(17):1475-9. PubMed ID: 10469748
[TBL] [Abstract][Full Text] [Related]
54. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines.
Julian-Reynier C; Eisinger F; Moatti JP; Sobol H
Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786
[TBL] [Abstract][Full Text] [Related]
55. Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
Carpenter KM; Eisenberg S; Weltfreid S; Low CA; Beran T; Stanton AL
Health Psychol; 2014 Sep; 33(9):1003-11. PubMed ID: 23772886
[TBL] [Abstract][Full Text] [Related]
56. Re: Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation carriers.
Foulkes WD
J Natl Cancer Inst; 2003 Sep; 95(17):1344; author reply 1344. PubMed ID: 12953090
[No Abstract] [Full Text] [Related]
57. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
Lu KH; Garber JE; Cramer DW; Welch WR; Niloff J; Schrag D; Berkowitz RS; Muto MG
J Clin Oncol; 2000 Jul; 18(14):2728-32. PubMed ID: 10894872
[TBL] [Abstract][Full Text] [Related]
58. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
59. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
[TBL] [Abstract][Full Text] [Related]
60. Prevention and genetic testing for breast cancer: variations in medical decisions.
Bouchard L; Blancquaert I; Eisinger F; Foulkes WD; Evans G; Sobol H; Julian-Reynier C
Soc Sci Med; 2004 Mar; 58(6):1085-96. PubMed ID: 14723904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
